| Autor: | Paul S. Hoffman, T. D. Sitland, N. Burford, L. Best, S. J. O. V. Van Zanten, L. Agocs, Des Leddin, G. S. Sandha, D. Mahoney, R. Leblanc |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
inorganic chemicals
medicine.medical_specialty Physiology Chemical structure Spirillaceae chemistry.chemical_element Pharmacology digestive system Gastroenterology Bismuth Pepsin Internal medicine medicine biology business.industry Helicobacter pylori equipment and supplies bacterial infections and mycoses biology.organism_classification digestive system diseases In vitro Mechanism of action chemistry biology.protein medicine.symptom Gastritis business |
| Zdroj: | Digestive Diseases and Sciences. 43:2727-2732 |
| ISSN: | 0163-2116 |
| DOI: | 10.1023/a:1026667714603 |
| Popis: | The recognition of the role of Helicobacter pylori in the pathogenesis of peptic ulcer disease has led to renewed interest in bismuth pharmacology since bismuth compounds have both anti-Helicobacter pylori and ulcer healing properties. The precise chemical structure of current bismuth compounds is not known. This has hindered the development of new and potentially more efficacious formulations. We have created two new compounds, 2-chloro-1,3-dithia-2-bismolane (CDTB) and 1,2-[bis(1,3-dithia-2-bismolane)thio]ethane (BTBT), with known structure. In a rat model of gastric ulceration, BTBT was comparable to, and CDTB was significantly less effective than colloidal bismuth subcitrate in healing cryoprobe-induced ulcers. However, both BTBT and CDTB inhibited H. pylori growth in vitro at concentrations |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink